NASDAQ:RVNC Revance Therapeutics (RVNC) Stock Price, News & Analysis $3.92 +0.16 (+4.26%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$3.72▼$4.1350-Day Range$2.34▼$4.3452-Week Range$2.30▼$24.87Volume1.77 million shsAverage Volume1.89 million shsMarket Capitalization$409.44 millionP/E RatioN/ADividend YieldN/APrice Target$11.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Revance Therapeutics alerts: Email Address Revance Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside193.4% Upside$11.50 Price TargetShort InterestBearish15.65% of Shares Sold ShortDividend StrengthN/ASustainability-0.88Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.83) to ($0.74) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.35 out of 5 starsMedical Sector145th out of 936 stocksPharmaceutical Preparations Industry60th out of 436 stocks 4.3 Analyst's Opinion Consensus RatingRevance Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 4 buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageRevance Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Revance Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted15.65% of the outstanding shares of Revance Therapeutics have been sold short.Short Interest Ratio / Days to CoverRevance Therapeutics has a short interest ratio ("days to cover") of 8.1.Change versus previous monthShort interest in Revance Therapeutics has recently increased by 7.64%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldRevance Therapeutics does not currently pay a dividend.Dividend GrowthRevance Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreRevance Therapeutics has received a 74.80% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Revance Therapeutics is -0.88. Previous Next 2.9 News and Social Media Coverage News SentimentRevance Therapeutics has a news sentiment score of 1.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Revance Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 3 people have searched for RVNC on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.MarketBeat Follows6 people have added Revance Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Revance Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.10% of the stock of Revance Therapeutics is held by insiders.Percentage Held by Institutions97.70% of the stock of Revance Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Revance Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Revance Therapeutics are expected to grow in the coming year, from ($1.83) to ($0.74) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Revance Therapeutics is -1.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Revance Therapeutics is -1.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Revance Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIWe’re in a code red crisis and 99% of Americans are clueless Folks, it's 2024… Things that we used to rely on - are failing us. Take the phasing out of fossil fuels… Matched with the destruction of oil refineries around the world… And the outright failure of solar and wind technologies… But there is just one solution… And right now governments around the world are stockpiling this resource at the fastest rate in DECADES! And how YOU can prepare for the next 2024 BOOM here! About Revance Therapeutics Stock (NASDAQ:RVNC)Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX that is in preclinical stage. The company also offers Resilient Hyaluronic Acid (RHA) dermal filler for the correction of moderate to severe dynamic facial wrinkles; and RHA Redensity, a dermal filler for the treatment of moderate to severe dynamic perioral rhytids. It has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.Read More RVNC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RVNC Stock News HeadlinesJuly 11, 2024 | investorplace.comStocks to Buy: 3 Breakout Stars to Transform Your PortfolioJune 14, 2024 | businesswire.comRevance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 26, 2024 | WealthPress (Ad)New trading system called MSFT, NVDA & MSFTLook 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.May 28, 2024 | businesswire.comRevance to Participate in Upcoming Investor ConferencesMay 22, 2024 | investorplace.comThe 100%+ Club: Piper Sandler's 3 Top Picks for Triple-Digit GainsMay 12, 2024 | investorplace.com3 Underappreciated Stocks That Could 10x in 10 YearsMay 10, 2024 | finance.yahoo.comRevance Therapeutics Reports Q1 2024 Financial Results: Revenue Growth Amidst Rising Operating ...May 10, 2024 | finance.yahoo.comRevance Therapeutics, Inc. (NASDAQ:RVNC) Q1 2024 Earnings Call TranscriptJuly 26, 2024 | WealthPress (Ad)New trading system called MSFT, NVDA & MSFTLook 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.May 9, 2024 | msn.comRVNC Stock Earnings: Revance Therapeutics Beats EPS, Misses Revenue for Q1 2024May 9, 2024 | msn.comRevance Therapeutics GAAP EPS of -$0.58, revenue of $51.94MMay 9, 2024 | businesswire.comRevance Reports First Quarter 2024 Financial Results, Provides Corporate UpdateMay 9, 2024 | businesswire.comRevance Expands into the U.S. Therapeutics Market with the Launch of DAXXIFY® for the Treatment of Cervical DystoniaMay 8, 2024 | markets.businessinsider.comRevance Therapeutics is about to announce earnings — here's what Wall Street expectsMay 2, 2024 | businesswire.comRevance to Release First Quarter 2024 Financial Results on Thursday, May 9, 2024May 2, 2024 | money.usnews.comRevance Therapeutics IncApril 12, 2024 | finance.yahoo.comRevance Therapeutics, Inc. (NASDAQ:RVNC) is favoured by institutional owners who hold 63% of the companyApril 12, 2024 | businesswire.comRevance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual MeetingSee More Headlines Receive RVNC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Revance Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/26/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:RVNC CUSIPN/A CIK1479290 Webwww.revance.com Phone(615) 724-7755Fax510-742-3401Employees597Year FoundedN/APrice Target and Rating Average Stock Price Target$11.50 High Stock Price Target$20.00 Low Stock Price Target$8.00 Potential Upside/Downside+203.4%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($3.63) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-323,990,000.00 Net Margins-134.10% Pretax Margin-137.23% Return on EquityN/A Return on Assets-44.70% Debt Debt-to-Equity RatioN/A Current Ratio5.37 Quick Ratio4.64 Sales & Book Value Annual Sales$234.04 million Price / Sales1.69 Cash FlowN/A Price / Cash FlowN/A Book Value($1.73) per share Price / Book-2.19Miscellaneous Outstanding Shares104,450,000Free Float99,122,000Market Cap$395.87 million OptionableOptionable Beta0.98 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Mark J. Foley (Age 59)CEO & Director Comp: $1.26MMr. Tobin C. Schilke (Age 49)CFO & Principal Accounting Officer Comp: $731.58kMr. Dwight O. Moxie (Age 48)Chief Legal Officer & General Counsel Comp: $713.82kJessica SerraHead of Investor Relations & ESGMs. Jeanie D. HerbertSenior Director of Investor Relations & Corporate CommunicationsMs. Taryn ConwayVice President of MarketingMs. Amie KrauseChief People OfficerDr. Conor GallagherHead of Medical Affairs & AestheticsDr. David A. Hollander M.B.A. (Age 49)M.D., Chief Medical Officer of Global Therapeutics Franchise Lead Ms. Erica Jordan (Age 47)Chief Commercial Officer More ExecutivesKey CompetitorsHeron TherapeuticsNASDAQ:HRTXArcturus TherapeuticsNASDAQ:ARCTMersana TherapeuticsNASDAQ:MRSNShattuck LabsNASDAQ:STTKGeneration BioNASDAQ:GBIOView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 68,451 shares on 7/26/2024Ownership: 0.357%Nisa Investment Advisors LLCBought 18,077 shares on 7/20/2024Ownership: 0.018%RF&L Wealth Management LLCBought 15,000 shares on 7/19/2024Ownership: 0.046%Mirador Capital Partners LPBought 72,355 shares on 7/13/2024Ownership: 0.069%DNB Asset Management ASBought 12,201 shares on 7/5/2024Ownership: 0.058%View All Insider TransactionsView All Institutional Transactions RVNC Stock Analysis - Frequently Asked Questions How have RVNC shares performed this year? Revance Therapeutics' stock was trading at $8.79 on January 1st, 2024. Since then, RVNC stock has decreased by 55.4% and is now trading at $3.92. View the best growth stocks for 2024 here. How were Revance Therapeutics' earnings last quarter? Revance Therapeutics, Inc. (NASDAQ:RVNC) released its quarterly earnings results on Thursday, May, 9th. The biopharmaceutical company reported ($0.54) EPS for the quarter, beating the consensus estimate of ($0.66) by $0.12. The biopharmaceutical company had revenue of $51.94 million for the quarter, compared to analysts' expectations of $55.64 million. What is Mark Foley's approval rating as Revance Therapeutics' CEO? 7 employees have rated Revance Therapeutics Chief Executive Officer Mark Foley on Glassdoor.com. Mark Foley has an approval rating of 82% among the company's employees. Who are Revance Therapeutics' major shareholders? Revance Therapeutics' top institutional investors include Bank of New York Mellon Corp (0.36%), Mirador Capital Partners LP (0.07%), DNB Asset Management AS (0.06%) and RF&L Wealth Management LLC (0.05%). Insiders that own company stock include Mark J Foley, Tobin Schilke, Dustin S Sjuts, Dwight Moxie, Erica Jordan, Carey Oconnor Kolaja, Angus C Russell and Aubrey Rankin. View institutional ownership trends. How do I buy shares of Revance Therapeutics? Shares of RVNC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Revance Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Revance Therapeutics investors own include Evolus (EOLS), Exelixis (EXEL), SCYNEXIS (SCYX), AbbVie (ABBV), Myovant Sciences (MYOV), Nektar Therapeutics (NKTR) and Sorrento Therapeutics (SRNE). This page (NASDAQ:RVNC) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Revance Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Revance Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
